Improving lung cancer treatment decisions and patient quality of life
Official title: Optimizing treatment decisions and quality-adjusted life years through improved lung cancer staging
Funded at Massachusetts General Hospital · NIH-10899827 · Data updated 2026-11-12
This study is looking at two different ways to take samples from lymph nodes in patients with early to mid-stage lung cancer to see which method helps doctors make better treatment decisions and improve patient outcomes.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | July 1, 2024 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $81,256 |
| NIH project number | 1F32CA290759-01 |
| Project ID | NIH-10899827 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with stage I-III non-small cell lung cancer who require lymph node staging.
✕Less likely to help
Patients with advanced lung cancer beyond stage III or those who are not candidates for biopsy procedures may not benefit from this research.
What this research studies
This research investigates how two different biopsy procedures, endobronchial ultrasound guided transbronchial node aspiration (EBUS) and mediastinoscopy, can affect treatment decisions for patients with stage I-III non-small cell lung cancer (NSCLC). By comparing these methods, the study aims to determine which procedure better detects the extent of cancer spread to lymph nodes and how this impacts patient outcomes. The research will utilize data from approximately 2,200 patients to analyze the effectiveness and risks associated with each procedure, ultimately aiming to enhance the quality-adjusted life years for patients. Patients will be monitored for changes in treatment decisions based on the biopsy results.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment decisions and better quality of life for lung cancer patients.
How similar studies have gone: Previous research has shown promising results in improving treatment outcomes through enhanced staging techniques, indicating that this approach may yield significant benefits.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Rudasill, Sarah Elizabeth — Massachusetts General Hospital
- Study coordinator: Rudasill, Sarah Elizabeth
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.